Related references
Note: Only part of the references are listed.KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma
Hanfeng Guan et al.
BLOOD (2010)
RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells
Alessio Papi et al.
CANCER LETTERS (2010)
MCC-555-induced NAG-1 expression is mediated in part by KLF4
Maria Cekanova et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Role for Kruppel-Like Factor 4 in Determining the Outcome of p53 Response to DNA Damage
Qibing Zhou et al.
CANCER RESEARCH (2009)
Putative Tumor-Suppressive Function of Kruppel-Like Factor 4 in Primary Lung Carcinoma
Wenxian Hu et al.
CLINICAL CANCER RESEARCH (2009)
KLF4-dependent, PPARγ-induced expression of GPA33 in colon cancer cell lines
Julie Rageul et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Effect of ligand troglitazone on peroxisome proliferator-activated receptor γ expression and cellular growth in human colon cancer cells
Mei Ming et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
KLF4, p21 and context-dependent opposing forces in cancer
BD Rowland et al.
NATURE REVIEWS CANCER (2006)
Emerging role of KLF4 in human gastrointestinal cancer
DY Wei et al.
CARCINOGENESIS (2006)
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene
BD Rowland et al.
NATURE CELL BIOLOGY (2005)
15-Deoxy-Δ12,14 prostaglandin J2 up-regulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor γ by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells
ZY Chen et al.
MOLECULAR PHARMACOLOGY (2005)
Downregulation and growth inhibitory effect of epithelial-type Kruppel-like transcription factor KLF4, but not KLF5, in bladder cancer
S Ohnishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer:: a phase II study
HJ Burstein et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity
DT Dang et al.
ONCOGENE (2003)
Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer
N Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2002)
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
D Panigrahy et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1
M Toyota et al.
LIFE SCIENCES (2002)
Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo
A Itami et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells
K Ohta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Roles of PPARs in health and disease
S Kersten et al.
NATURE (2000)
Share Paper
